Articles tagged "CD20"

2022 American Transplant Congress
Desensitization Protocol to Prevent Severe Oliguric Antibody-Mediated Rejection
H. Ishida¹, K. Unagami¹, T. Kamzawa¹, K. Omoto¹, H. Shimizu¹, K. Tanabe²
¹Tokyo Womens, Tokyo 162-8666, Japan, ²Tokyo Women's Medical University, Tokyo, Japan
*Purpose: Antibody-mediated rejection in a case with a positive crossmatch test can be severe and result in sudden onset of oliguria and sometimes, anuria, leading…
2022 American Transplant Congress
Pre-Emptive Rituximab Use for Epstein-Barr Virus (EBV) Viremia in Cardiothoracic Solid Organ Transplant Recipients
B. Astorga, A. Loethen, L. Potter
University of Chicago Medicine, Chicago, IL
*Purpose: EBV viremia is associated with potentially life-threatening post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. The utility of rituximab for treating EBV viremia in…
2022 American Transplant Congress
Validation of Donor Specific Antibody Characteristics Associated with Deleterious Outcomes: A Single Center Study of 940 Kidney Allograft Recipients
P. Lamba¹, I. Lamba¹, R. Friedlander², V. Sharma³, J. Lee², J. B. Lee⁴, C. Hartono⁵, M. Thangamani⁶, D. Sawinski², T. Salinas⁷, M. Suthanthiran⁸, D. Dadhania⁹
¹Nephrology, Hypertension and Transplantation, New York Presbyterian/Weill Cornell Medicine, New York, NY, ²New York Presbyterian/Weill Cornell Medicine, New York, NY, ³The Rogosin Inst Cornell UMC, New York, NY, ⁴Rogosin Institute, New York, NY, ⁵New York Presbyterian Hospital-Weill Cornell, New York, NY, ⁶Cornell, New York, NY, ⁷Nephrology, NY Presbyterian- Weill Cornell, New York, NY, ⁸Weill Cornell Med Ctr., New York, NY, ⁹Weill Cornell Medicine - NYPH, New York, NY
*Purpose: A reproducibility crisis is pervasive in scientific literature. We aimed to investigate whether the DSA characteristics we previously associated with antibody mediated rejection (AMR)…
2022 American Transplant Congress
The Addition of Bortezomib to a Rituximab Based Antibody Mediated Rejection Treatment Protocol in Lung Transplant
M. Galle, P. Stracener, K. Warrior, J. Lyons
Loyola University Medical Center, Maywood, IL
*Purpose: To evaluate the impact of antibody mediated rejection (AMR) treatment with rituximab combined with bortezomib vs. rituximab alone on patient survival, graft survival, and…
2021 American Transplant Congress
Dissecting the Intrarenal Immune Response to Viral Infected Cells in Pediatric BK Virus-associated Nephropathy (BKVAN)
D. M. Okamura¹, S. W. Jackson¹, V. R. Dharnidharka², J. M. Smith¹
¹Pediatric Nephrology, Seattle Children's Hospital & Research Institute, Seattle, WA, ²Pediatric Nephrology, 2St. Louis Children’s Hospital, Washington University School of Medicine, St. Louis, MO
*Purpose: BKVAN is not only a cause of acute renal allograft injury but is a recognized cause of chronic allograft disease and in some patients,…
2021 American Transplant Congress
Impact of Rituximab Induction Therapy on Donor-specific Anti-HLA Antibodies in Abo-compatible Kidney Transplant Recipients
T. Yagisawa¹, T. Kanzawa¹, K. Unagami², M. Furusawa¹, M. Inui¹, H. Ishida², K. Tanabe¹
¹Department of Urology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Organ Transplant Medicine, Tokyo Women's Medical University, Tokyo, Japan
*Purpose: Development of de novo donor-specific anti-HLA antibodies (dnDSA) after kidney transplantation remains strongly associated with antibody-mediated rejection (AMR), which leads to poor graft outcome.…
2020 American Transplant Congress
T and B Lymphocyte Dynamics after Genetically-Modified Pig-To-Baboon Kidney Xenotransplantation with an Anti-CD40mAb-Based Immunosuppressive Regimen
A. Jagdale¹, H. Iwase¹, H. Nguyen¹, T. Yamamoto¹, D. Ayares², D. Anderson¹, D. Eckhoff¹, D. Cooper¹, H. Hara¹
¹Surgery, University of Alabama at birmingham, Birmingham, AL, ²Revivicor, Blacksburg, VA, VA
*Purpose: We have evaluated recovery of T and B lymphocytes and their subsets after depletion by anti-thymocyte globulin (ATG) and an anti-CD20mAb (Rituximab), followed by…
2020 American Transplant Congress
Rapid Preparation to Undergo ABO-Incompatible Living Donor Liver Transplantation for Acute Liver Failure
H. Hung¹, C. Lee², Y. Wang¹, J. Lee², C. Cheng¹, T. Wu¹, T. Wu¹, H. Chou¹, K. Chan¹, W. Lee²
¹Chang-gung Hospital, Taoyuan, Taiwan, ²Chang-gung Hospital, Taiyuan, Taiwan
*Purpose: Acute liver failure is a life-threatening condition and urgent liver transplantation is needed to save lives. In the circumstance of deceased and ABO-compatible (ABO-C)…
2020 American Transplant Congress
Association between Response to Rituximab and Risk of Antibody-Mediated Rejection in ABO-Incompatible Living Kidney Transplantation
Y. Kakuta¹, M. Okumi¹, T. Kanzawa¹, K. Unagami², H. Ishida², K. Tanabe¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan, ²Organ Transplant Regulation, Tokyo Women's Medical University, Tokyo, Japan
*Purpose: Owing to limited organ availability, ABO-incompatible living kidney transplantation (ABO-ILKT) has been used extensively. Various forms of preconditioning therapies have been used alone or…
2020 American Transplant Congress
Impact of Rituximab and Apheresis Techniques in Acute Rejection Rates in ABO Incompatible Living Donor Kidney Transplant
I. Revuelta¹, E. De Sousa-Amorim¹, M. Lozano², D. Cucchiari¹, J. Cid², L. Peri³, E. Palou⁴, M. Musquera³, J. Martorell⁵, J. M. Campistol¹, F. Oppenheimer¹, F. Diekmann¹
¹Renal Transplant Unit, Department of Nephrology and Kidney Transplant, Hospital Clinic, Barcelona, Spain, ²Apheresis and Cellular Therapy Unit, Hospital Clinic, Barcelona, Spain, ³Department of Urology, Hospital Clinic, Barcelona, Spain, ⁴Histocompatibility Lab. Department of Immunology, Hospital Clinic, Barcelona, Spain, ⁵Histocompatibility Lab, Department of Immunology, Hospital Clinic, Barcelona, Spain
*Purpose: ABO incompatibility (ABOi) is a widespread option of living kidney donor transplantation (LKDT). However, controversies in rejection, and death-censored graft survival rates are published,…